A Dose Escalation Study of Sorafenib (BAY 43-9006, NSC 724772) in Nomotensive Patients With Advanced Malignancies
PRIMARY OBJECTIVES:
I. Determine whether increasing the dose of sorafenib tosylate increases the plasma
steady-state concentration in patients with advanced solid tumors.
II. Determine whether increasing the dose of this drug affects blood pressure in these
patients.
SECONDARY OBJECTIVES:
I. Determine whether the variability in blood pressure elevation is due to pharmacokinetic
or pharmacodynamic variability.
II. Compare the toxicity and differences in pharmacokinetics of delivering a higher dose of
this drug per day (using two different schedules) vs delivering the currently recommended
dose of this drug.
III. Investigate mechanisms of sorafenib tosylate-induced hypophosphatemia with serial
measurements of phosphate metabolism (no longer assessed as of 4/29/2009) in these patients,
detailed baseline measurements in all patients, and detailed evaluations of patients
developing grade 3 or greater hypophosphatemia.
IV. Detect subclinical effects of this drug on measures of thyroid function. V. Identify
biomarkers predicting the categorization of patient response.
OUTLINE: This is a randomized, dose-escalation study.
Patients receive oral sorafenib tosylate twice daily on days 1-7 and once on day 8. Patients
not experiencing at least one grade 2 or higher toxicity during the initial sorafenib
treatment are randomized to 1 of 3 dose-escalated treatment arms.
ARM I: Patients receive higher-dose oral sorafenib tosylate twice daily on days 15-36.
ARM II: Patients receive standard-dose oral sorafenib tosylate three times daily on days
15-36.
ARM III: (closed to accrual as of 4/29/2009) Patients receive standard-dose oral sorafenib
tosylate twice daily on days 15-36.
In all arms, treatment repeats every 3 weeks in the absence of disease progression or
unacceptable toxicity.
Patients undergo ambulatory blood pressure monitoring at baseline, on days 7, 14, and 21,
and at 6 and 12 months. Blood samples are collected periodically throughout study and
evaluated for pharmacokinetic studies, thyroid function, serum markers, and phosphate
metabolism*. CT perfusion imaging is performed at baseline, week 6, week 12, and then every
8-12 weeks thereafter.
NOTE: * Phosphate metabolism no longer assessed as of 4/29/2009.
After completion of study treatment, patients are followed every 4 weeks for 1 year and then
every 3 months thereafter.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Changes in BP
BP will first be calculated for each subject as BP after 1 week of treatment minus BP before that treatment dose. Then, for each randomized group separately, the BP changes in the two study phases will be compared using paired t-tests.
From baseline to day 21
No
Michael Maitland
Principal Investigator
University of Chicago Comprehensive Cancer Center
United States: Food and Drug Administration
NCI-2009-00221
NCT00436579
October 2006
Name | Location |
---|---|
University of Chicago Comprehensive Cancer Center | Chicago, Illinois 60637-1470 |